ResearcherKyushu UniversityNo recent work listed
Masaharu Murata
Matched on OpenAlex author ID A5109801747. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 2 papers
Papers 4
- FOXO3 is essential for CD44 expression in pancreatic cancer cells. Co-author DOI 10.1038/onc.2016.426↗
- Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
- Design and Function of Engineered Protein Nanocages as a Drug Delivery System for Targeting Pancreatic Cancer Cells via Neuropilin-1. Co-author DOI 10.1021/mp5007129↗
- Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1097/mpa.0000000000000092↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Makoto Hashizume · 3 shared papers, 2014–2017 · strength 0.14
- Paper Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Pr… DOI 10.1053/j.gastro.2017.01.010↗
- Paper Design and Function of Engineered Protein Nanocages as a Drug Delivery System for Targeting Pancreatic Cancer Cells via… DOI 10.1021/mp5007129↗
- Paper Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. DOI 10.1097/mpa.0000000000000092↗
- Kenoki Ohuchida · 3 shared papers, 2014–2017 · strength 0.14
- Paper Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Pr… DOI 10.1053/j.gastro.2017.01.010↗
- Paper Design and Function of Engineered Protein Nanocages as a Drug Delivery System for Targeting Pancreatic Cancer Cells via… DOI 10.1021/mp5007129↗
- Paper Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. DOI 10.1097/mpa.0000000000000092↗
- Shuntaro Tsukamoto · 1 shared paper, 2017 · strength 0.06
- Motofumi Kumazoe · 1 shared paper, 2017 · strength 0.06
- Hirofumi Tachibana · 1 shared paper, 2017 · strength 0.06
- Mai Yamashita · 1 shared paper, 2017 · strength 0.06
- Kohei Horioka · 1 shared paper, 2017 · strength 0.05
- Sho Endo · 1 shared paper, 2017 · strength 0.05
- Takashi Okumura · 1 shared paper, 2017 · strength 0.05
- Masafumi Sada · 1 shared paper, 2017 · strength 0.05
- Hiromichi Nakayama · 1 shared paper, 2017 · strength 0.05
- Chika Iwamoto · 1 shared paper, 2017 · strength 0.05
- Yoshinao Oda · 1 shared paper, 2017 · strength 0.05
- Kazuhiro Koikawa · 1 shared paper, 2017 · strength 0.05
- Masafumi Nakamura · 1 shared paper, 2017 · strength 0.05
- Kohei Nakata · 1 shared paper, 2017 · strength 0.05
- Shin Takesue · 1 shared paper, 2017 · strength 0.05
- Yusuke Mizuuchi · 1 shared paper, 2017 · strength 0.05
- Biao Zheng · 1 shared paper, 2017 · strength 0.05
- Toshiya Abe · 1 shared paper, 2017 · strength 0.05
- Yoshihiro Miyasaka · 1 shared paper, 2017 · strength 0.05
- Takao Ohtsuka · 1 shared paper, 2017 · strength 0.05
- Takashi Murakami · 1 shared paper, 2015 · strength 0.05
- Yoshinori Fujimura · 1 shared paper, 2014 · strength 0.04
- Naoki Ikenaga · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.